The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
160
0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
Change from baseline to End of Treatment (EOT) Visit on the 24-hour average Systolic Blood Pressure (SBP) in mmHg
Time frame: Baseline, Up to 6 weeks
Change from baseline to EOT Visit on the daytime average SBP in mmHg
Time frame: Baseline, Up to 6 weeks
Change from baseline to EOT Visit on the seated resting average SBP in mmHg
Time frame: Baseline, Up to 6 weeks
Change from baseline to EOT Visit on the nighttime average SBP in mmHg
Time frame: Baseline, Up to 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Science 37
Culver City, California, United States
M3 Wake Research
Encino, California, United States
So Cal Clinical Research
Huntington Beach, California, United States
Long Beach Research Institute
Lakewood, California, United States
Stanford School of Medicine
Redwood City, California, United States
TriValley Sleep Center
San Ramon, California, United States
SDS Clinical Trials, Inc.
Santa Ana, California, United States
FWD Clinical Research
Boca Raton, Florida, United States
Meris Clinical Research, LLC
Brandon, Florida, United States
Ocean Wellness Center
Miami, Florida, United States
...and 33 more locations